IN2014CN04374A - - Google Patents
Info
- Publication number
- IN2014CN04374A IN2014CN04374A IN4374CHN2014A IN2014CN04374A IN 2014CN04374 A IN2014CN04374 A IN 2014CN04374A IN 4374CHN2014 A IN4374CHN2014 A IN 4374CHN2014A IN 2014CN04374 A IN2014CN04374 A IN 2014CN04374A
- Authority
- IN
- India
- Prior art keywords
- fragments
- antibodies
- ligand
- bind
- inhibit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566912P | 2011-12-05 | 2011-12-05 | |
| PCT/IB2012/056956 WO2013084151A2 (en) | 2011-12-05 | 2012-12-04 | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04374A true IN2014CN04374A (enExample) | 2015-09-04 |
Family
ID=47561692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4374CHN2014 IN2014CN04374A (enExample) | 2011-12-05 | 2012-12-04 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP2788381A2 (enExample) |
| JP (1) | JP2015500830A (enExample) |
| KR (1) | KR20140099315A (enExample) |
| CN (1) | CN104093742A (enExample) |
| AR (1) | AR089085A1 (enExample) |
| AU (1) | AU2012349739A1 (enExample) |
| BR (1) | BR112014013495A8 (enExample) |
| CA (1) | CA2857939A1 (enExample) |
| EA (1) | EA201491120A1 (enExample) |
| IL (1) | IL232950A0 (enExample) |
| IN (1) | IN2014CN04374A (enExample) |
| MX (1) | MX2014006731A (enExample) |
| SG (1) | SG11201402784WA (enExample) |
| TW (1) | TW201331225A (enExample) |
| UY (1) | UY34488A (enExample) |
| WO (1) | WO2013084151A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2941030C (en) | 2014-02-28 | 2025-05-13 | Merus N.V. | ANTIBODIES THAT BIND TO EGFR AND ERBB3 |
| DK3805268T3 (da) * | 2014-02-28 | 2025-01-20 | Merus Nv | Antistof, der binder erbb-2 og erbb-3 |
| US20170291956A1 (en) | 2014-07-16 | 2017-10-12 | David Livingston | HER3 Inhibition in Low-grade Serous Ovarian Cancers |
| CN104530237B (zh) * | 2014-12-31 | 2017-09-05 | 百泰生物药业有限公司 | 抗Her1的治疗性抗体 |
| JP7296728B2 (ja) | 2015-10-23 | 2023-06-23 | メルス ナムローゼ フェンノートシャップ | 癌の成長を抑制する結合分子 |
| JP6729926B2 (ja) * | 2016-05-12 | 2020-07-29 | 国立大学法人神戸大学 | ＥｒｂＢ３活性化に伴うシグナルの伝達抑制物質及びそのスクリーニング方法 |
| KR102469700B1 (ko) * | 2016-09-15 | 2022-11-23 | 우니베르지테트 스튜트가르트 | Her3에 대한 항원 결합 단백질 |
| KR101923641B1 (ko) * | 2016-11-25 | 2018-11-29 | 재단법인 목암생명과학연구소 | 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| JP7737220B2 (ja) | 2017-03-31 | 2025-09-10 | メルス ナムローゼ フェンノートシャップ | ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体 |
| EP3625264B9 (en) | 2017-05-17 | 2023-10-25 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
| RS66708B9 (sr) | 2017-08-09 | 2025-08-29 | Merus Nv | Antitela koja se vezuju za egfr i cmet |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| JP2012525432A (ja) * | 2009-04-29 | 2012-10-22 | トレリス バイオサイエンス リミテッド ライアビリティー カンパニー | ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体 |
| KR101806323B1 (ko) * | 2009-11-13 | 2017-12-07 | 다이이치 산쿄 유럽 게엠베하 | Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법 |
| KR101764453B1 (ko) * | 2010-04-09 | 2017-08-02 | 아베오 파마슈티컬즈, 인크. | 항-erbb3 항체 |
| TW201302793A (zh) * | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| NO2707391T3 (enExample) * | 2011-05-13 | 2018-04-07 | ||
| CA2842860A1 (en) * | 2011-07-28 | 2013-01-31 | Sea Lane Biotechnologies, Llc | Sur-binding proteins |
-
2012
- 2012-12-04 EP EP12816130.4A patent/EP2788381A2/en not_active Withdrawn
- 2012-12-04 MX MX2014006731A patent/MX2014006731A/es unknown
- 2012-12-04 JP JP2014545420A patent/JP2015500830A/ja active Pending
- 2012-12-04 AU AU2012349739A patent/AU2012349739A1/en not_active Abandoned
- 2012-12-04 EA EA201491120A patent/EA201491120A1/ru unknown
- 2012-12-04 BR BR112014013495A patent/BR112014013495A8/pt not_active Application Discontinuation
- 2012-12-04 TW TW101145508A patent/TW201331225A/zh unknown
- 2012-12-04 CN CN201280068966.8A patent/CN104093742A/zh active Pending
- 2012-12-04 CA CA2857939A patent/CA2857939A1/en not_active Abandoned
- 2012-12-04 WO PCT/IB2012/056956 patent/WO2013084151A2/en not_active Ceased
- 2012-12-04 SG SG11201402784WA patent/SG11201402784WA/en unknown
- 2012-12-04 KR KR1020147018336A patent/KR20140099315A/ko not_active Withdrawn
- 2012-12-04 UY UY0001034488A patent/UY34488A/es not_active Application Discontinuation
- 2012-12-04 IN IN4374CHN2014 patent/IN2014CN04374A/en unknown
- 2012-12-05 AR ARP120104559A patent/AR089085A1/es unknown
-
2014
- 2014-06-02 IL IL232950A patent/IL232950A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2857939A1 (en) | 2013-06-13 |
| WO2013084151A3 (en) | 2014-01-03 |
| JP2015500830A (ja) | 2015-01-08 |
| EP2788381A2 (en) | 2014-10-15 |
| SG11201402784WA (en) | 2014-06-27 |
| TW201331225A (zh) | 2013-08-01 |
| EA201491120A1 (ru) | 2015-07-30 |
| WO2013084151A2 (en) | 2013-06-13 |
| AR089085A1 (es) | 2014-07-30 |
| UY34488A (es) | 2013-07-31 |
| BR112014013495A2 (pt) | 2017-06-13 |
| BR112014013495A8 (pt) | 2017-06-13 |
| AU2012349739A1 (en) | 2014-06-26 |
| KR20140099315A (ko) | 2014-08-11 |
| MX2014006731A (es) | 2015-06-04 |
| IL232950A0 (en) | 2014-07-31 |
| CN104093742A (zh) | 2014-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013084151A3 (en) | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3 | |
| IN2014CN04373A (enExample) | ||
| EA201200195A1 (ru) | АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ | |
| GEP201706605B (en) | Antibodies for epidermal growth factor receptor 3 (her3) | |
| PH12012500881A1 (en) | Antibodies binding preferentially human csf1r extracellular domain 4 and their use | |
| PH12014501410A1 (en) | Compositions and methods for antibodies targeting factor p | |
| MY159396A (en) | Compositions and methods for antibodies targeting complement protein c5 | |
| MX343858B (es) | Anticuerpos anti-il-23. | |
| UA106070C2 (uk) | Антитіло, що специфічно зв'язується з egfr і her3 | |
| PH12013500660B1 (en) | Methods of treating psoriasis using il-17 antagonists | |
| MX360403B (es) | Proteinas de union a amiloide beta. | |
| SG184310A1 (en) | Antibodies that bind human cd27 and uses thereof | |
| TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
| EA201291067A1 (ru) | Гуманизированные антигенсвязывающие белки к миостатину | |
| UY32914A (es) | Anticuerpos que se usan específicamente al receptor epha2 | |
| EA200901119A1 (ru) | АНТИТЕЛА ПРОТИВ ErbB3 И ИХ ПРИМЕНЕНИЕ | |
| MX358739B (es) | Proteinas de union a amiloide beta. | |
| MX347454B (es) | Anticuerpos monoclonales inhibidores anti-factor xii-xiia. | |
| WO2009002380A3 (en) | Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies | |
| CY1121167T1 (el) | Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων | |
| MX2010005927A (es) | Construcciones de union de antigenos. | |
| UA106529C2 (uk) | Гуманізоване антитіло до cxcr4 для лікування раку | |
| PH12013500616A1 (en) | Antibody compositions and methods of use | |
| WO2015048008A3 (en) | Binding molecules specific for her3 and uses thereof | |
| MX2016008418A (es) | Metodos y reactivos para el radiomarcaje. |